Trial · NCT00654381
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in HbA1c at Week 12 | Placebo | 0.63 | Standard Error 0.08 | Percent | |
| Change From Baseline in HbA1c at Week 12 | Linagliptin 5mg | -0.24 | Standard Error 0.06 | Percent | |
| Change From Baseline in HbA1c at Week 12 | Linagliptin 10 mg | -0.25 | Standard Error 0.06 | Percent | |
| Change From Baseline in HbA1c at Week 26 | Linagliptin 5mg | -0.13 | Standard Error 0.07 | Percent | |
| Change From Baseline in HbA1c at Week 26 | Linagliptin 10 mg | -0.19 | Standard Error 0.07 | Percent | |
| Change From Baseline in HbA1c at Week 26 | Voglibose | 0.19 | Standard Error 0.07 | Percent | |
| Relative Efficacy Response of HbA1c at Week 12 | Placebo | HbA1c <7.0% | 8 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Linagliptin 5mg | HbA1c <7.0% | 42 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Linagliptin 10 mg | HbA1c <7.0% | 56 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Placebo | HbA1c <6.5% | 0 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Linagliptin 5mg | HbA1c <6.5% | 15 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Linagliptin 10 mg | HbA1c <6.5% | 18 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Placebo | HbA1c reduction from baseline ≥0.5% | 7 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Linagliptin 5mg | HbA1c reduction from baseline ≥0.5% | 91 | Participants | |
| Relative Efficacy Response of HbA1c at Week 12 | Linagliptin 10 mg | HbA1c reduction from baseline ≥0.5% | 94 | Participants | |
| Relative Efficacy Response of HbA1c at Week 26 | Linagliptin 5mg | HbA1c <7.0% | 48 | Participants | |
| Relative Efficacy Response of HbA1c at Week 26 | Linagliptin 10 mg | HbA1c <7.0% | 54 | Participants | |
| Relative Efficacy Response of HbA1c at Week 26 | Voglibose | HbA1c <7.0% | 36 | Participants | |
| Relative Efficacy Response of HbA1c at Week 26 | Linagliptin 5mg | HbA1c <6.5% | 15 | Participants | |
| Relative Efficacy Response of HbA1c at Week 26 | Linagliptin 10 mg | HbA1c <6.5% | 21 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00654381/results